Centeon Kankakee, Ill. plant resumes production pursuant to consent decree with FDA.
CENTEON TO RESUME PRODUCTION AT KANKAKEE, IL. PLANT UNDER CONSENT DECREE between FDA and the blood products company; the consent decree will be filed the week of Jan. 27. The Rhone-Poulenc Rorer and Hoechst joint venture Centeon halted operations at the Kankakee facility in October following a series of plasma product recalls due to suspected bacterial contamination from vial cracks ("The Pink Sheet" Oct. 14, 1996, T&G-7).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth